Mechanisms and clinical research progress of SGLT2i in improving exercise tolerance in patients with heart failure

Exercise intolerance is a primary clinical manifestation of heart failure (HF) that significantly reduces patients’ quality of life and independently predicts adverse prognosis. Despite reducing mortality and hospitalization, guideline-directed medical therapy has limited effects on exercise capacity. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have consistently reduced HF hospitalization and improved patient-reported symptoms and health status, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ), whereas their effects on objective exercise capacity, such as 6-minute walk distance (6MWD) and peak oxygen consumption (peak VO 2 ), have been less consistent across trials, with pooled effects below commonly cited minimal clinically important difference thresholds. This review compares the evidence maturity of the hemodynamic and peripheral skeletal muscle pathways through which SGLT2i may enhance exercise tolerance. Regarding hemodynamics, the reduction in exercise-induced pulmonary capillary wedge pressure (PCWP) and may improve right ventricular–pulmonary artery (RV-PA) coupling provide a plausible mechanism, although direct evidence is mainly from HFpEF and mediation has not been demonstrated across the broader HF population. Regarding skeletal muscle, animal and human biopsy studies suggest potential modulation of AMPK signaling and reduced myofiber atrophy, but the independent contribution remains unvalidated. These differences in evidence maturity highlight the need to distinguish mechanistic findings, patient-reported health status, and objective functional outcomes when evaluating SGLT2i.

Authors

Institutions

Publication Details

Journal
Frontiers in Cardiovascular Medicine
Published
2026-11-12
DOI
https://doi.org/10.3389/fcvm.2026.2006661
Primary Topic
Heart Failure Treatment and Management
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Mechanisms and clinical research progress of SGLT2i in improving exercise tolerance in patients with heart failure

Feng Ru, Ruowen Yuan, Xiaowei Zhang, Liyuan Tao
Frontiers in Cardiovascular Medicine
Heart Failure Treatment and Management
article

Mechanisms and clinical research progress of SGLT2i in improving exercise tolerance in patients with heart failure

Feng Ru, Ruowen Yuan, Xiaowei Zhang, Liyuan Tao
article en

Abstract

Exercise intolerance is a primary clinical manifestation of heart failure (HF) that significantly reduces patients’ quality of life and independently predicts adverse prognosis. Despite reducing mortality and hospitalization, guideline-directed medical therapy has limited effects on exercise capacity. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) have consistently reduced HF hospitalization and improved patient-reported symptoms and health status, as assessed by the Kansas City Cardiomyopathy Questionnaire (KCCQ), whereas their effects on objective exercise capacity, such as 6-minute walk distance (6MWD) and peak oxygen consumption (peak VO 2 ), have been less consistent across trials, with pooled effects below commonly cited minimal clinically important difference thresholds. This review compares the evidence maturity of the hemodynamic and peripheral skeletal muscle pathways through which SGLT2i may enhance exercise tolerance. Regarding hemodynamics, the reduction in exercise-induced pulmonary capillary wedge pressure (PCWP) and may improve right ventricular–pulmonary artery (RV-PA) coupling provide a plausible mechanism, although direct evidence is mainly from HFpEF and mediation has not been demonstrated across the broader HF population. Regarding skeletal muscle, animal and human biopsy studies suggest potential modulation of AMPK signaling and reduced myofiber atrophy, but the independent contribution remains unvalidated. These differences in evidence maturity highlight the need to distinguish mechanistic findings, patient-reported health status, and objective functional outcomes when evaluating SGLT2i.

Frontiers in Cardiovascular MedicineVol. 13
Lanzhou University Second Hospital (CN), Lanzhou University (CN)
Lanzhou Science and Technology Bureau
Good health and well-being
Heart Failure Treatment and Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon